Biosensor Based Clinical-decision Support For Patients With Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$691,933.00
Summary
Heart Failure (HF) is a progressive disease and a major global public health concern. HF accounts for a substantial number of hospitalisations, major healthcare resource utilisation and costs. We aim to engineer biosensor platform to stratify the risk in HF patients will revolutionise current management of HF by providing the cardiologist information to risk stratify patients based on protein signature. This will lead to a substantial paradigm shift in clinical practice.
Development of planar patch-clamp electrophysiology to investigate liposome-based artificial nanosensor devices. This project aims to characterise the interaction of transport proteins with unsupported lipid bilayer membranes. This will provide the basis for a novel biosensor utilising mechanosensitive ion channels incorporated into an artificial lipid bilayer membrane. To support this outcome, the project will develop the planar patch-clamp electrophysiology recording techniques suitable for l ....Development of planar patch-clamp electrophysiology to investigate liposome-based artificial nanosensor devices. This project aims to characterise the interaction of transport proteins with unsupported lipid bilayer membranes. This will provide the basis for a novel biosensor utilising mechanosensitive ion channels incorporated into an artificial lipid bilayer membrane. To support this outcome, the project will develop the planar patch-clamp electrophysiology recording techniques suitable for liposomes. This provides a significant PhD training opportunity and brings an international focus to the development of planar patch-clamp electrophysiology in Australia. The project has significant commercial potential by developing both the planar patch-clamp electrophysiology techniques for liposomes and producing a novel biomimetic mechanosensitive biosensor.Read moreRead less
Novel Carbon Nanotube Composite Materials: Elucidation of key properties for device development. As the former co-director of CSIRO Nanotechnology indicated to the Sydney Morning Herald in 2003, 'Nanotechnology will lead us into a very different future.' The proposed research on nanomaterial interactions and biomolecular incorporation protocols will provide a foundation for future bioelectronic devices. Imagine healthcare of human diseases when nanocomponents enable the design of new platforms f ....Novel Carbon Nanotube Composite Materials: Elucidation of key properties for device development. As the former co-director of CSIRO Nanotechnology indicated to the Sydney Morning Herald in 2003, 'Nanotechnology will lead us into a very different future.' The proposed research on nanomaterial interactions and biomolecular incorporation protocols will provide a foundation for future bioelectronic devices. Imagine healthcare of human diseases when nanocomponents enable the design of new platforms for devices that give point-of-care diagnosis, or the impact on the semiconductor industry with the creation of flexible electronics. Educational outreach is an important aim of the project, providing effective research training for early career researchers.Read moreRead less
Osteoarthritis Compass: Predicting Personalized Disease Onset And Progression With Future Capacity For Clinical Use.
Funder
National Health and Medical Research Council
Funding Amount
$860,231.00
Summary
Knee osteoarthritis (OA) is common, painful, and costly. General guidelines for knee OA management exist but cannot be personalized to the patient. New computer modelling methods enable prediction of knee OA onset and progression on a patient by patient basis but need further testing. Our aims are to 1) apply these new computer modelling methods to legacy datasets acquired from patient groups at risk of, and with, knee OA, and 2) make these models simple and fast enough to be clinically useful.
Single-cell Optical Window Imaging In CDK1-FRET Biosensor Mice To Assess Tissue Stiffness And Optimise Delivery And Therapeutic Response To Gemcitabine/Abraxane In Pancreatic Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$676,979.00
Summary
Inefficient drug response in solid tumour tissue is commonly a limiting factor in the clinical effectiveness of cancer therapies. Using cutting-edge imaging technology and 3D models that mimic the disease, we have mapped areas of poor drug response within distinct regions of tumours. Here, we pinpoint and specifically target key factors limiting efficient drug targeting in order to improve the encouraging anti-cancer profile of the new drug combination Gemcitabine/Abraxane in pancreatic cancer.
Real-time Optical Window Imaging Of AKT-FRET Biosensor Mice To Maximise PI3K/AKT Drug Targeting Within The Hypoxic Microenvironment Of Pancreatic Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$683,447.00
Summary
Inefficient drug response in solid tumour tissue is often a limiting factor in the clinical effectiveness of cancer therapies. Using cutting-edge imaging technology and 3D models that mimic the disease, we have mapped areas of poor drug response within distinct regions of tumours with low oxygen levels known as hypoxia. Here, we will specifically target factors limiting efficient drug targeting in these areas to improve the encouraging anti-cancer profile of AKT inhibitors in pancreatic cancer.
Biosensor Imaging In Preclinical Pancreatic Cancer Targeting: Taking Cancer Targeting To New Dimensions.
Funder
National Health and Medical Research Council
Funding Amount
$640,210.00
Summary
Using cutting-edge imaging technology and 3D models that mimic cancer, we can map areas of poor drug response within distinct 'stages' or regions of tumours. Here, we pinpoint and specifically target key factors limiting efficient drug response in order to improve the encouraging anti-cancer profile of new or current drugs in pancreatic cancer.
PARP And PI3K Inhibition In Pancreatic Cancer: Intravital Insights And ‘fine-tune’ Priming Using AKT And Single/double-strand DNA Break Biosensor Mice.
Funder
National Health and Medical Research Council
Funding Amount
$760,505.00
Summary
Inefficient drug response in solid tumour tissue is often a limiting factor in the clinical effectiveness of cancer therapies. Using cutting-edge imaging technology and 3D models that mimic the disease, we can map areas of poor drug response within distinct regions of tumours with chemotherapy. Here, we will shift factors limiting efficient drug targeting in these areas to improve the encouraging anti-cancer profile of PI3K and DNA repair inhibitors in pancreatic cancer.
Non-invasive diagnosis using micropatches that sample biomarkers from skin. We are developing a technology called the micropatch that is laid onto the surface of the skin. When the patch is pulled away, it retains proteins found in the subsurface skin layers. We believe that by analysing these proteins we will be able to diagnose diseases like cancer earlier and therefore have a better chance of treating them successfully. The process is painless, and doctors already use it to give drugs and vac ....Non-invasive diagnosis using micropatches that sample biomarkers from skin. We are developing a technology called the micropatch that is laid onto the surface of the skin. When the patch is pulled away, it retains proteins found in the subsurface skin layers. We believe that by analysing these proteins we will be able to diagnose diseases like cancer earlier and therefore have a better chance of treating them successfully. The process is painless, and doctors already use it to give drugs and vaccines. In the future we hope that our technology will be simple enough for routine diagnosis, even in the Outback where doctors are hundreds of kilometres awayRead moreRead less